LIB Therapeutics Announces Positive Lerodalcibep Results from Two Phase 3 LIBerate Studies at the 92nd European Atherosclerosis Society Congress
LIB Therapeutics Announces Lerodalcibep Abstracts Accepted for Presentation at the 92nd European Atherosclerosis Society Congress
LIB Therapeutics Announces Positive Results from LIBerate-HR Study: A 52-Week, Placebo-Controlled Registration-Enabling Trial of Lerodalcibep at Late-Breaking Session at American College of Cardiology 2024
LIB Therapeutics To Participate in Piper Sandler Virtual Cardio Day Focused on Highlights from ACC 2024 Conference
LIB Therapeutics Announces Abstracts Accepted for Presentation at the American College of Cardiology Scientific Session 2024
LIB Therapeutics and Partner Hasten Biopharmaceuticals Announce Lerodalcibep Clinical Trial Application Acceptance by the Center for Drug Evaluation at the National Medical Products Administration in China
LIB Therapeutics Announces Abstracts Accepted for Presentation
LIB Therapeutics Announces Appointment of Ingrid Choong, PhD as Chief Business Officer as Company Prepares BLA for Lerodalcibep
LIB Announces Completion of the Global Phase 3 LIBerate Program of Lerodalcibep
LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China